<DOC>
	<DOCNO>NCT02213289</DOCNO>
	<brief_summary>The purpose study determine doctor use result special test subject tumor tissue , look specific abnormality tumor , choose specific drug target work abnormality ( call molecular profiling ) see effect ( good and/or bad ) target drug subject cancer give standard chemotherapy .</brief_summary>
	<brief_title>PANGEA-IMBBP : Personalized Antibodies Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial Biologics Beyond Progression</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Ramucirumab</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>1 . Histologically confirm metastatic gastric esophagogastric junction ( type I , II , III Siewert ) adenocarcinoma 2 . Newlydiagnosed chemonaïve recurrent curativeintent surgery &gt; 6 month completion adjuvant therapy ( include chemotherapy and/or radiotherapy ) No prior treatment target agent Patients start first line mFOLFOX6 therapy ( +/trastuzumab HER2 amplify tumor ) may consider trial participation receive 4 dos therapy time consent screen . 3 . Measurable metastatic disease RECIST criterion , Must amenable ultrasound CTguided biopsy one metastatic lesion Peritoneal disease sole site occult metastasis present malignant ascites acceptable cell block tumor cell obtain show &gt; 20 % viable tumor cell . 4 . ECOG PS 0,1 5 . Age &gt; 18 year 6 . Patients must normal organ marrow function define : granulocyte &gt; 1,2500/mcL platelet &gt; 100,000/mcL total bilirubin &lt; 1.5 x ULN , &lt; 1.8 x ULN liver metastasis AST ( SGOT ) /ALT ( SGPT ) &lt; 2.5 X ULN without liver metastasis ; &lt; 5 X ULN liver metastasis creatinine within normal institutional limit ( &lt; 1.5 ) OR creatinine clearance &gt; 50 mL/min/1.73m2 , ( creatinine level normal ) INR : &lt; 1.5 ( patient warfarin need convert LMWH study participation eligible ) 7 . Consent baseline metastatic progressive disease biopsy ( metastatic/progressing lesion ) enable biomarker assessment treatment assignment ( time point baseline , PD1 , PD2 , PD3 ) well correlative study . • Consent baseline serial blood draw plasma/serum/whole blood banking correlative study 8 . Ability understand willingness sign write informed consent document consent serial nature propose PANGEA treatment first , second third line therapy tolerate . 9 . Ability comply requirement protocol , assess investigator patient sign consent form . 10 . If history exposure anthracyclines perioperative treatment , follow cumulative dos anthracyclines must less : Epirubicin &lt; 720 mg/m2 Doxorubicin liposomal doxorubicin &lt; 360 mg/m2 Mitoxantrone &gt; 120 mg/m2 idarubicin &gt; 90 mg/m2 If one anthracycline use , cumulative dose must exceed equivalent 360 mg/m2 doxorubicin . 11 . Cardiac Ejection Fraction &gt; 50 % ( HER2+ patient ) assess echocardiogram , MUGA scan , cardiac MRI 12 . Willingness use effective reliable method contraception ( For appropriate method contraception consider acceptable see Appendix B ) . Both men woman member race ethnic group eligible trial . 1 . No CVA within 6 month , recent MI within 6 month 2 . No currently active second malignancy 3 . No uncontrolled intercurrent illness infection 4 . No peripheral edema &gt; grade 2 baseline . 5 . No peripheral neuropathy &gt; grade 2 baseline . 6 . No diarrhea &gt; grade 2 baseline .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Gastric</keyword>
	<keyword>Esophagogastric</keyword>
</DOC>